REGN
Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
$707.06
+3.02% today
Updated 2026-04-29
Market cap
$79.46B
P/E ratio
18.11
P/S ratio
5.54x
EPS (TTM)
$41.49
Dividend yield
0.46%
52W range
$475 – $820
Volume
0.7M
Regeneron Pharmaceuticals Inc (REGN) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+20.2%
Last 4 quarters
Revenue YoY growth
+2.5%
Most recent quarter
EPS YoY growth
-5.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.8%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+4.8%
2025-08-01
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-01-30 | $11.44 | +8.7% | $749.44 | $755.02 | +0.7% |
| 2025-10-30 | $11.83 | +22.3% | $652.91 | $651.80 | -0.2% |
| 2025-08-01 | $12.89 | +52.7% | $545.46 | $571.54 | +4.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $10.52 | $11.44 | +8.7% | $3.88B | +2.5% |
| 2025-09-30 | $9.67 | $11.83 | +22.3% | $3.75B | +0.9% |
| 2025-06-30 | $8.44 | $12.89 | +52.7% | $3.68B | +3.6% |
| 2025-03-31 | $8.48 | $8.22 | -3.1% | $3.03B | -3.7% |
| 2024-12-31 | $11.19 | $12.07 | +7.9% | $3.79B | +10.3% |
| 2024-09-30 | $11.70 | $12.46 | +6.5% | $3.72B | +10.6% |
| 2024-06-30 | $10.61 | $11.56 | +9.0% | $3.55B | +12.3% |
| 2024-03-31 | $10.09 | $9.55 | -5.4% | $3.15B | — |
| 2023-12-31 | $10.73 | $11.86 | +10.5% | $3.43B | — |
| 2023-09-30 | $10.72 | $11.59 | +8.1% | $3.36B | — |
| 2023-06-30 | $9.84 | $10.24 | +4.1% | $3.16B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $46.75 | $16.1B | +11.9% | 25 | high |
| 2027 (E) | $54.83 | $17.7B | +10.3% | 25 | high |
| 2028 (E) | $62.50 | $19.3B | +8.8% | 25 | medium |
| 2029 (E) | $70.00 | $20.8B | +8.1% | 25 | medium |
| 2030 (E) | $77.50 | $22.4B | +7.7% | 25 | medium |
Frequently asked questions
Has Regeneron Pharmaceuticals Inc beaten earnings estimates?
Regeneron Pharmaceuticals Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +20.2% over the last 4 quarters.
How does REGN stock react to earnings?
REGN stock has moved an average of +1.8% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Regeneron Pharmaceuticals Inc's revenue growth rate?
Regeneron Pharmaceuticals Inc reported year-over-year revenue growth of +2.5% in its most recent quarter, with EPS growing -5.2% year-over-year.
What is the expected EPS for REGN in 2026?
Analysts expect Regeneron Pharmaceuticals Inc to report EPS of $46.75 for fiscal year 2026, on revenue of $16.1B, based on estimates from 25 analysts.